FOXA1 as a therapeutic target for breast cancer

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 4, 2007, Pages 507-514

  Nakshatri, Harikrishna ^a   Badve, Sunil ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; FOXA1; Luminal type A

Indexed keywords

ANTIESTROGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTROGEN RECEPTOR ALPHA; FORKHEAD TRANSCRIPTION FACTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; INSULIN; LIAROZOLE FUMARATE; RETINOIC ACID; UVOMORULIN;

BREAST CANCER; CANCER CLASSIFICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CLINICAL TRIAL; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE TARGETING; HORMONE DEPENDENCE; HUMAN; NONHUMAN; PROGNOSIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS;

EID: 33947630304     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.4.507     Document Type: Review

References (60)

1. PEGRAM MD, PIETRAS R, BAJAMONDE A et al.: Targeted therapy: wave of the future. J. Clin. Oncol. (2005) 23(8):1776-1781.
2. NAHTA R, ESTEVA FJ: HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res. (2006) 8(6):215.
3. ALI S, COOMBES RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer (2002) 2(2):101-112.
4. SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001) 98(19):10869-10874.
5. KAESTNER KH, KNOCHEL W, MARTINEZ DE: Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. (2000) 14(2):142-146.
6. CARROLL JS, LIU XS, BRODSKY AS et al.: Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell (2005) 122(1):33-43.
7. LAGANIERE J, DEBLOIS G, LEFEBVRE C et al.: From the cover: location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. USA (2005) 102(33):11651-11656.
8. LANTZ KA, KAESTNER KH: Winged-helix transcription factors and pancreatic development. Clin. Sci. (Lond) (2005) 108(3):195-204.
9. WEIGEL D, JURGENS G, KUTTNER F et al.: The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell (1989) 57(4):645-658.
10. CLARK KL, HALAY ED, LAI E et al.: Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature (1993) 364(6436):412-420.
11. KAESTNER KH: The hepatocyte nuclear factor 3(HNF3 or FOXA) family in metabolism. Trends Endocrinol. Metab. (2000) 11(7):281-285.
12. BESNARD V, WERT SE, KAESTNER KH et al.: Stage-specific regulation of respiratory epithelial cell differentiation by Foxa1. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 289(5):L750-L759.
13. GAO N, ISHII K, MIROSEVICH Jet al.: Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 132(15):3431-3443.
14. LEE CS, FRIEDMAN JR, FULMER JT et al.: The initiation of liver development is dependent on Foxa transcription factors. Nature (2005) 435(7044):944-947.
15. TOMPERS DM, FOREMAN RK, WANG Q et al.: Foxd3 is required in the trophoblast progenitor cell lineage of the mouse embryo. Dev. Biol. (2005) 285(1):126-137.
16. PYZIK M, PICCIRILLO CA: The TGF-β1/Foxp3 regulatory axis in immune self-tolerance: implications for health and disease. Inflamm. Allergy Drug Targets (2006) 5(3):167-177.
17. GREER EL, BRUNET A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene (2005) 24(50):7410-7425.
18. LAOUKILI J, STAHL M, MEDEMA RH: FoxM1: At the crossroads of ageing and cancer. Biochim. Biophys. Acta (2007) 1775(1):92-102.
19. ORMESTAD M, ASTORGA J, LANDGREN H et al.: Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development (2006) 133(5):833-843.
20. PAN G, LI J, ZHOU Y et al.: A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. FASEB J. (2006) 20(10):1730-1732.
21. BLEUL CC, CORBEAUX T, REUTER A et al.: Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature (2006) 441(7096):992-996.
22. COSTA RH, GRAYSON DR, DARNELL JE Jr: Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and α1-antitrypsin genes. Mol. Cell. Biol. (1989) 9(4):1415-1425.
23. LAI E, PREZIOSO VR, SMITH E et al.: HNF-3A, a hepatocyte-enriched transcription factor of novel structure is regulated transcriptionally. Genes Dev. (1990) 4(8):1427-1436.
24. COSTA RH, GRAYSON DR: Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. Nucleic Acids Res. (1991) 19(15):4139-4145.
25. PAULWEBER B, SANDHOFER F, LEVY-WILSON B: The mechanism by which the human apolipoprotein B gene reducer operates involves blocking of transcriptional activation by hepatocyte nuclear factor 3. Mol. Cell. Biol. (1993) 13(3):1534-1546.
26. DUNCAN SA, NAVAS MA, DUFORT D et al.: Regulation of a transcription factor network required for differentiation and metabolism. Science (1998) 281(5377):692-695.
27. LEVINSON-DUSHNIK M, BENVENISTY N: Involvement of hepatocyte nuclear factor 3 in endoderm differentiation of embryonic stem cells. Mol. Cell. Biol. (1997) 17(7):3817-3822.
28. WOLFRUM C, BESSER D, LUCA E et al.: Insulin regulates the activity of forkhead transcription factor Hnf-3β/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc. Natl. Acad. Sci. USA (2003) 100(20):11624-11629.
29. WORKMAN JL: Nucleosome displacement in transcription. Genes Dev. (2006) 20(15):2009-2017.
30. CIRILLO LA, LIN FR, CUESTA I et al.: Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell (2002) 9(2):279-289.
31. CARROLL JS, BROWN M: Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. (2006) 20(8):1707-1714.
32. MANGELSDORF DJ, THUMMEL C, BEATO M et al.: The nuclear receptor superfamily: the second decade. Cell (1995) 83(6):835-839.
33. CARROLL JS, MEYER CA, SONG J et al.: Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. (2006) 38(11):1289-1297.
34. GAO N, ZHANG J, RAO MA et al.: The role of hepatocyte nuclear factor-3α (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. (2003) 17(8):1484-1507.
35. HOLMQVIST PH, BELIKOV S, ZARET KS et al.: FoxA1 binding to the MMTV LTR modulates chromatin structure and transcription. Exp. Cell Res. (2005) 304(2):593-603.
36. ZHANG L, RUBINS NE, AHIMA RS et al.: Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab. (2005) 2(2):141-148.
37. MIROSEVICH J, GAO N, GUPTA A et al.: Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 66(10):1013-1028.
38. DOANE AS, DANSO M, LAL P et al.: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene (2006) 25(28):3994-4008.
39. LAZAREVICH NL., CHEREMNOVA OA, VARGA EV et al.: Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology (2004) 39(4):1038-1047.
40. LIN L, MILLER CT, CONTRERAS JI et al.: The hepatocyte nuclear factor 3α gene, HNF3α (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. (2002) 62(18):5273-5279.
41. NEMENOFF RA, WINN RA: Role of nuclear receptors in lung tumourigenesis. Eur. J. Cancer (2005) 41(16):2561-2568.
42. SCHWARTZ AG, PRYSAK GM, MURPHY et al.: Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin. Cancer Res. (2005) 11(20):7280-7287.
43. KAWAI H, ISHII A, WASHIYA K et al.: Estrogen receptor α and β are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. (2005) 11(14):5084-5089.
44. LACROIX M, LECLERCQ G: About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer. Mol. Cell. Endocrinol. (2004) 219(1-2):1-7.
45. OH DS, TROESTER MA, USARY J et al.: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. (2006) 24(11):1656-1664.
46. KOUROS-MEHR H, SLORACH EM, STERNLICHT MD et al.: GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell (2006) 127(5):1041-1055.
47. BADVE S, TURBIN D, MORIMIYA A et al.: Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer. J. Clin. Oncol. (2006) 24(18S):Abstract 539.
48. XIA W, BACUS S, HEGDE P et al.: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA (2006) 103(20):7795-7800.
49. CUI X, SCHIFF R, ARPINO G et al.: Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. (2005) 23(30):7721-7735.
50. CLARKE RB, HOWELL A, POTTEN CS et al.: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. (1997) 57(22):4987-4991.
51. WILLIAMSON EA, WOLF I, O'KELLY J et al.: BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). Oncogene (2006) 25(9):1391-1399.
52. LIU YN, LEE WW, WANG CY et al.: Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene (2005) 24(56):8277-8290.
53. KAESTNER KH, KATZ J, LIU Y et al.: Inactivation of the winged helix transcription factor HNF3α affects glucose homeostasis and islet glucagon gene expression in vivo. Genes Dev. (1999) 13(4):495-504.
54. LIN EY, JONES JG, LI P et al.: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. (2003) 163(5):2113-2126.
55. LIN SC, LEE KF, NIKITIN AY et al.: Somatic mutation of p53 leads to estrogen receptor α-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. (2004) 64(10):3525-3532.
56. ASSELIN-LABAT ML, SUTHERLAND KD, BARKER H et al.: Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. (2007) 9(2):201-209.
57. JACOB A, BUDHIRAJA S, QIAN X et al.: Retinoic acid-mediated activation of HNF-3α during EC stem cell differentiation. Nucleic Acids Res. (1994) 22(11):2126-2133.
58. ROSENAUER A, NERVI C, DAVISON K et al.: Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor α expression. Cancer Res. (1998) 58(22):5110-5116.
59. GOSS PE, STRASSER K, MARQUES R et al.: Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res. Treat. (2000) 64(2):177-188.
60. KNOWLDEN JM, HUTCHESON IR, BARROW D et al.: Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 146(11):4609-4618.